Navigation Links
Martek Signs Sole-Source Supply Agreement with Fonterra
Date:12/10/2009

Martek Biosciences Corporation (NASDAQ: MATK) announced today that it has entered into a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited for the use of Martek’s products in Fonterra’s infant formulas and milk-based Anmum™ Materna products for pregnant and nursing mothers.

Columbia, MD (Vocus) December 10, 2009 -- Martek Biosciences Corporation (NASDAQ: MATK) announced today that it has entered into a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited for the use of Martek’s products in Fonterra’s infant formulas and milk-based Anmum™ Materna products for pregnant and nursing mothers.

Fonterra’s infant formulas, featuring life’sDHA™ and life’sARA™, will be available in Malaysia, Indonesia and China.

Fonterra’s Anmum™ Materna products for pregnant and nursing mothers, featuring life’sDHA, will be available in Indonesia, Taiwan, Hong Kong, the Philippines, Malaysia, Vietnam, Singapore, Thailand and China.

“Martek is a leading global supplier of DHA and ARA. Infant formulas containing Martek’s
life’sDHA and life’sARA can be found in more than 75 countries worldwide, and we continue to expand our international presence in the infant formula and perinatal markets,” said Ethan Leonard, vice president of pediatric nutrition for Martek. “Our sole-source supply arrangement with Fonterra further demonstrates that companies worldwide understand the importance of adding Martek’s DHA and ARA to infant formula and perinatal products for infant health and development.”

Naturally present in human breast milk, DHA (docosahexaenoic acid), and ARA (arachidonic acid) are fatty acids important to infant development and growth. Clinical studies have demonstrated numerous benefits for infants receiving DHA and ARA supplemented formula, including improved mental and visual development.
DHA also is important throughout pregnancy, particularly in the third trimester when significant brain growth occurs. Maternal DHA supplementation during pregnancy and nursing significantly enhances the level of DHA available to the fetus and infant. Studies have shown that maternal DHA supplementation may improve infant developmental outcomes, such as eye-hand coordination, motor skills and attention span.

Martek's blend of DHA and ARA, life’sDHA & life’sARA, is the only source of these nutrients currently used in U.S. infant formula, and is present in more than 95 percent of infant formula sold in the U.S. Martek’s life’sDHA can also be found around the world in a range of supplements and other products intended for use during pregnancy and breastfeeding.

Fonterra is the world’s leading exporter of dairy products and responsible for more than a third of international dairy trade. Its dairy farmers have long been known for producing quality milk and today Fonterra is a world leader in dairy commodities and premium ingredients, and has regional consumer brands businesses in Australasia, Asia, the Middle East and Latin America. Fonterra’s global supply chain stretches from farms all over New Zealand to customers and consumers in more than 140 countries. Fonterra currently manufactures the Anmum™ brand of premium milk formulas for pregnant and nursing mothers, as well as for infants and toddlers.

Martek Biosciences Corporation is a leader in the innovation and development of DHA and ARA and has developed patented technology for the production and use of these ingredients. DHA omega-3 products promote health and wellness through every stage of life and ARA omega-6 products support growth and development in infants and children. The company produces life'sDHA™, a sustainable vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, perinatal products, and supplements, and life’sARA™, a sustainable vegetarian source of ARA omega-6, for use in infant formula and growing up milks. For more information on Martek Biosciences, visit http://www.martek.com/. For more information on products containing lifesDHA and life’sARA, visit www.lifesdha.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

# # #

Read the full story at http://www.prweb.com/releases/dairy_fonterra/martek_biosciences/prweb3321614.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Martek to Announce Fourth Quarter and Fiscal Year 2009 Results
2. Martek Announces Addition to Its Board of Directors
3. Martek to Present at Two Upcoming Investor Conferences
4. Martek Announces Settlement of Patent Dispute with Capsugel France
5. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
6. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions
7. Martek to Announce Third Quarter 2009 Results
8. Martek Signs Sole-Source ARA Supply Agreement with Puleva Food S.L.
9. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
10. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
11. EU Committee Approves New Food Applications for Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Martek Signs Sole-Source Supply Agreement with Fonterra
(Date:2/18/2017)... MONTREAL , February 18, 2017 ... von intrazellulären Zytokinen bei adoptiven Zelltherapie-Studien, Poster legt metaproteomische ... ... Biosciences Inc. heute bekanntgab, wird Dr. Yoav Peretz ... Methoden in der Entwicklung von Assays zum Nachweis intrazellulärer ...
(Date:2/18/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics ... , and Rest of World. Annual estimates and forecasts are ... analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... , Feb. 17, 2017  If only ... tumor had a mutation-conferring resistance to chemotherapy, thousands ... genomics research has focused on finding these mutations ... even from circulating tumor DNA in blood — ... oncology therapeutics. Unfortunately, however, detecting these ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... EIT ... framework primarily aimed at the agricultural industry. Pilot studies are about to get under ... through IoT, Big Data and 5G innovations. The concept is expected to be transferred ...
Breaking Biology Technology:
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):